{"id":1638,"date":"2024-07-17T21:14:50","date_gmt":"2024-07-17T13:14:50","guid":{"rendered":"https:\/\/flcube.com\/?p=1638"},"modified":"2024-10-28T12:16:29","modified_gmt":"2024-10-28T04:16:29","slug":"biocytogen-strikes-exclusive-deal-with-sotio-biotech-for-next-gen-adcs","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=1638","title":{"rendered":"Biocytogen Strikes Exclusive Deal with SOTIO Biotech for Next-Gen ADCs"},"content":{"rendered":"\n

Biocytogen (HKG: 2315), a leading biopharmaceutical company based in China, has announced a strategic research collaboration and licensing agreement with the Netherlands-based SOTIO Biotech B.V. The partnership grants SOTIO an exclusive option to license multiple fully human bispecific antibodies generated through Biocytogen’s proprietary RenLite platform. These antibodies will be utilized by SOTIO to develop next-generation antibody-drug conjugates (ADCs) targeting solid tumors.<\/p>\n\n\n\n

The RenLite platform, known for producing bispecific antibodies, has caught the attention of SOTIO, which aims to leverage this technology to create cutting-edge treatments for cancer. The agreement also encompasses an option for SOTIO to use Biocytogen’s ADC platform, further expanding the scope of potential therapies.<\/p>\n\n\n\n

Under the terms of this agreement, Biocytogen stands to receive upfront payments, potential milestone payments reaching up to USD 325.5 million, and royalties based on net sales in the low single digits. The collaboration will see SOTIO and Biocytogen working closely during the research phase of the bispecific programs, with SOTIO taking the lead on nonclinical and clinical development, manufacturing, and commercialization of the ADC products.<\/p>\n\n\n\n

This strategic partnership exemplifies the growing trend of global collaborations in the biopharmaceutical industry, aimed at developing innovative treatments for cancer. It also highlights the recognition of Chinese biopharmaceutical companies’ R&D capabilities on the international stage. As Biocytogen and SOTIO join forces, they aim to accelerate the discovery and delivery of novel therapies to patients in need, potentially transforming the treatment landscape for various types of solid tumors.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Biocytogen (HKG: 2315), a leading biopharmaceutical company based in China, has announced a strategic research…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,1519,1214,513],"class_list":["post-1638","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-adc-xdc","tag-biocytogen-pharmaceuticals","tag-hkg-2315","tag-sotio-biotech"],"yoast_head":"\nBiocytogen Strikes Exclusive Deal with SOTIO Biotech for Next-Gen ADCs - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Biocytogen (HKG: 2315), a leading biopharmaceutical company based in China, has announced a strategic research collaboration and licensing agreement with the Netherlands-based SOTIO Biotech B.V. The partnership grants SOTIO an exclusive option to license multiple fully human bispecific antibodies generated through Biocytogen's proprietary RenLite platform. These antibodies will be utilized by SOTIO to develop next-generation antibody-drug conjugates (ADCs) targeting solid tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=1638\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biocytogen Strikes Exclusive Deal with SOTIO Biotech for Next-Gen ADCs\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=1638\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-17T13:14:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-28T04:16:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1638#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1638\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biocytogen Strikes Exclusive Deal with SOTIO Biotech for Next-Gen ADCs\",\"datePublished\":\"2024-07-17T13:14:50+00:00\",\"dateModified\":\"2024-10-28T04:16:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1638\"},\"wordCount\":257,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Biocytogen Pharmaceuticals\",\"HKG: 2315\",\"SOTIO Biotech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=1638#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1638\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=1638\",\"name\":\"Biocytogen Strikes Exclusive Deal with SOTIO Biotech for Next-Gen ADCs - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-07-17T13:14:50+00:00\",\"dateModified\":\"2024-10-28T04:16:29+00:00\",\"description\":\"Biocytogen (HKG: 2315), a leading biopharmaceutical company based in China, has announced a strategic research collaboration and licensing agreement with the Netherlands-based SOTIO Biotech B.V. The partnership grants SOTIO an exclusive option to license multiple fully human bispecific antibodies generated through Biocytogen's proprietary RenLite platform. These antibodies will be utilized by SOTIO to develop next-generation antibody-drug conjugates (ADCs) targeting solid tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1638#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=1638\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=1638#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biocytogen Strikes Exclusive Deal with SOTIO Biotech for Next-Gen ADCs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biocytogen Strikes Exclusive Deal with SOTIO Biotech for Next-Gen ADCs - Insight, China's Pharmaceutical Industry","description":"Biocytogen (HKG: 2315), a leading biopharmaceutical company based in China, has announced a strategic research collaboration and licensing agreement with the Netherlands-based SOTIO Biotech B.V. The partnership grants SOTIO an exclusive option to license multiple fully human bispecific antibodies generated through Biocytogen's proprietary RenLite platform. These antibodies will be utilized by SOTIO to develop next-generation antibody-drug conjugates (ADCs) targeting solid tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=1638","og_locale":"en_US","og_type":"article","og_title":"Biocytogen Strikes Exclusive Deal with SOTIO Biotech for Next-Gen ADCs","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=1638","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-07-17T13:14:50+00:00","article_modified_time":"2024-10-28T04:16:29+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=1638#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=1638"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biocytogen Strikes Exclusive Deal with SOTIO Biotech for Next-Gen ADCs","datePublished":"2024-07-17T13:14:50+00:00","dateModified":"2024-10-28T04:16:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=1638"},"wordCount":257,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Biocytogen Pharmaceuticals","HKG: 2315","SOTIO Biotech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=1638#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=1638","url":"https:\/\/flcube.com\/?p=1638","name":"Biocytogen Strikes Exclusive Deal with SOTIO Biotech for Next-Gen ADCs - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-07-17T13:14:50+00:00","dateModified":"2024-10-28T04:16:29+00:00","description":"Biocytogen (HKG: 2315), a leading biopharmaceutical company based in China, has announced a strategic research collaboration and licensing agreement with the Netherlands-based SOTIO Biotech B.V. The partnership grants SOTIO an exclusive option to license multiple fully human bispecific antibodies generated through Biocytogen's proprietary RenLite platform. These antibodies will be utilized by SOTIO to develop next-generation antibody-drug conjugates (ADCs) targeting solid tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=1638#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=1638"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=1638#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biocytogen Strikes Exclusive Deal with SOTIO Biotech for Next-Gen ADCs"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/1638","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1638"}],"version-history":[{"count":3,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/1638\/revisions"}],"predecessor-version":[{"id":6713,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/1638\/revisions\/6713"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1638"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1638"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1638"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}